Sign in Subscribe

metastatic

A collection of 142 issues

Australian registry study examines treatment patterns in early-onset CRC with liver metastases

Skip to content The CRC Digest ◇ RESEARCH Australian registry study examines treatment patterns in early-onset CRC with liver metastases A retrospective cohort study using the TRACC registry explored treatment timing, sequencing, and outcomes for early-onset CRC patients (≤50 years) with liver-only metastases compared to late-onset patients. (Med J Aust) This

Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC

Skip to content The CRC Digest ▸ TREATMENT Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC Telisotuzumab adizutecan, which delivers a topoisomerase inhibitor to c-MET-expressing tumor cells, achieved an objective response rate of 15.6% in 122 heavily pretreated metastatic colorectal cancer patients in a phase

Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic

CRC Research Update — August 19, 2026

Today's colorectal cancer research highlights

KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed

Skip to content The CRC Digest KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not

BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRC A randomized study compared encorafenib plus cetuximab and FOLFIRI against FOLFIRI with or without bevacizumab in patients with BRAF V600E-mutant colorectal cancer. (Annals of Oncology) This content is informational only

CRC Research Update — August 18, 2026

Today's colorectal cancer research highlights

Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib

Skip to content The CRC Digest ♥ LIVING WITH CRC Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib Researchers developed a weighted toxicity score to help patients and clinicians compare side effects between two later-line treatment options, supporting more informed treatment decisions in metastatic colorectal cancer. (Clinical Colorectal Cancer)

CRC Research Update — August 17, 2026

Today's colorectal cancer research highlights